Orelabrutinib
Primary Central Nervous System Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Primary Central Nervous System Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan National Cancer Institute (NCI) | Phase 2 | BB |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 2 | B |
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
Vorinostat National Cancer Institute (NCI) | Phase 2 | B |
METHOTREXATE National Cancer Institute (NCI) | Phase 2 | B |
View all 19 →
Same molecule, other indications
Orelabrutinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →